We are live on ! Find out more
VIR icon

Vir Biotechnology
VIR

204 hedge funds and large institutions have $2.09B invested in Vir Biotechnology in 2022 Q1 according to their latest regulatory filings, with 47 funds opening new positions, 84 increasing their positions, 44 reducing their positions, and 49 closing their positions.

New
Increased
Maintained
Reduced
Closed

91% more repeat investments, than reductions

Existing positions increased: 84 | Existing positions reduced: 44

62% more call options, than puts

Call options by funds: $16.7M | Put options by funds: $10.3M

1.66% more ownership

Funds ownership: 59.67% → 61.33% (+1.7%)

4% less first-time investments, than exits

New positions opened: 47 | Existing positions closed: 49

3% less funds holding

Funds holding: 210 → 204 (-6)

36% less capital invested

Capital invested by funds: $3.25B → $2.09B (-$1.16B)

43% less funds holding in top 10

Funds holding in top 10: 7 → 4 (-3)

Holders
204
Holders Change
-6
Holders Change %
-2.86%
% of All Funds
3.22%
Holding in Top 10
4
Holding in Top 10 Change
-3
Holding in Top 10 Change %
-42.86%
% of All Funds
0.06%
New
47
Increased
84
Reduced
44
Closed
49
Calls
$16.7M
Puts
$10.3M
Net Calls
+$6.41M
Net Calls Change
+$7.59M

Top Buyers

1
Millennium Management
Millennium Management
New York
+$112M
2
State Street
State Street
Massachusetts
+$49.4M
3
GF
Gates Foundation
Washington
+$26.1M
4
AllianceBernstein
AllianceBernstein
Tennessee
+$14M
5
Vanguard Group
Vanguard Group
Pennsylvania
+$12.7M

Top Sellers

1
Point72 Asset Management
Point72 Asset Management
Connecticut
-$86M
2
OIM
Oracle Investment Management
Connecticut
-$36M
3
Capital International Investors
Capital International Investors
California
-$34.9M
4
Morgan Stanley
Morgan Stanley
New York
-$19M
5
Citadel Advisors
Citadel Advisors
Florida
-$17.5M
Name Holding Trade Value Shares
Change 		Change in
Stake
SCA
151
Spearhead Capital Advisors
Florida
$229K +$264K +8,892 New
PCM
152
Prelude Capital Management
New York
$223K +$258K +8,684 New
PM
153
Parametrica Management
Hong Kong
$201K +$232K +7,823 New
Acadian Asset Management
154
Acadian Asset Management
Massachusetts
$197K +$229K +7,718 New
PHK
155
Point72 Hong Kong
Hong Kong
$176K +$203K +6,835 New
DCM
156
Dupont Capital Management
Delaware
$133K +$30.1K +1,014 +24%
AF
157
Allworth Financial
California
$131K +$146K +4,916 +2,672%
AIP
158
Ameritas Investment Partners
Nebraska
$121K – – –
MLICM
159
Metropolitan Life Insurance Company (MetLife)
New York
$101K -$342K -11,534 -75%
Lazard Asset Management
160
Lazard Asset Management
New York
$94K +$108K +3,631 +11,347%
Amundi
161
Amundi
France
$88K – – –
VEA
162
Virtus ETF Advisers
New York
$87K -$5.75K -194 -5%
SAM
163
Shell Asset Management
Netherlands
$75K -$12.7K -429 -13%
QT
164
Quantbot Technologies
New York
$64K +$73.9K +2,493 New
TLCM
165
Twin Lakes Capital Management
California
$56K – – –
LSA
166
Leonteq Securities AG
Switzerland
$51.4K +$54.9K +1,850 +1,233%
FCA
167
FinTrust Capital Advisors
South Carolina
$51K – – –
MCC
168
Money Concepts Capital
Florida
$44K +$51.2K +1,726 New
AF
169
Advisornet Financial
Minnesota
$32K – – –
ACM
170
Aquatic Capital Management
Illinois
$31K +$35.6K +1,200 New
Fifth Third Bancorp
171
Fifth Third Bancorp
Ohio
$26K +$11.1K +375 +60%
ACM
172
Anfield Capital Management
California
$17K +$19.3K +650 New
GWM
173
Geneos Wealth Management
Colorado
$16K – – –
Nisa Investment Advisors
174
Nisa Investment Advisors
Missouri
$11K -$29.4K -990 -69%
Daiwa Securities Group
175
Daiwa Securities Group
Japan
$10K – – –
5 6
7
8 9

VIR Hedge Fund Activity: Q1 2022 in Review

204 of the 6,340 institutional investors tracked by Wall St. Rank reported a position in Vir Biotechnology (VIR) for Q1 2022, worth a combined $2.09B — down 36% from $3.25B a quarter earlier.

Sellers outnumbered buyers: 49 funds closed out of VIR and 47 opened new positions — a net loss of 2 holders — while 44 trimmed existing stakes and 84 added.

The largest buyer was Millennium Management, adding an estimated $112M. The largest seller was Point72 Asset Management, exiting entirely with an estimated $86M sold.

  • 204 institutional investors held Vir Biotechnology (VIR) as of Q1 2022, down from 210 in Q4 2021.
  • Funds reported $2.09B of Vir Biotechnology stock for Q1 2022, down 36% quarter-over-quarter.
  • 47 funds opened new Vir Biotechnology positions in Q1 2022 and 49 closed out, a net change of -2 holders.
  • The largest Vir Biotechnology buyer in Q1 2022 was Millennium Management, an estimated $112M added.
  • The largest Vir Biotechnology seller in Q1 2022 was Point72 Asset Management, an estimated $86M sold.

Based on aggregated 13F filings for Q1 2022.